ZMUni Compliance Centre

At ZMUni, we value the trust and feedback of our partners as an important reflection of our professional services and long-term cooperation.   Recently, three partners from South Korea's beauty industry shared their recognition of ZMUni's regulatory support and project execution capabilities. Representing different segments of the beauty industry—a skincare brand, a cosmetics manufacturer, and an international beauty company—these collaborations demonstrate the diverse regulatory challenges companies may encounter when entering the China market.   From addressing regulatory changes and managing registration processes to preparing technical documentation for efficacy-based products, ZMUni continues to provide practical solutions to help global beauty companies

Entering China's cosmetic market requires a thorough understanding of regulatory requirements, documentation procedures, and compliance obligations. At ZMUni, we help global beauty brands navigate these challenges with professional consulting, transparent communication, and end-to-end regulatory support.   Recently, EDK SPA SOLUTION CO., LTD., a South Korean cosmetic company, shared a recommendation letter highlighting their experience working with ZMUni Compliance Centre.     Overcoming Regulatory Challenges with Professional Guidance   Before entering the Chinese market, EDK faced uncertainties regarding China's cosmetic registration procedures and complex documentation requirements.   Their cooperation with ZMUni began at a regulatory seminar organized by a Korean public institution,

South Korea's cosmetics industry continues to show strong global growth, with K-beauty brands gaining increasing recognition worldwide. In 2025, China became the second-largest export market for Korean cosmetics, with exports reaching approximately USD 2 billion, reflecting strong demand for innovative skincare and beauty products.   With extensive experience supporting Korean cosmetics brands, ZMUni helps K-beauty companies navigate China's regulatory landscape and achieve compliant market entry. In the first half of 2026, we supported a diverse portfolio of Korean brands, from globally recognized names to emerging beauty innovators and professional skincare companies, delivering tailored regulatory solutions for their China expansion.  

China's New Cosmetic Ingredient (NCI) market continued to expand in H1 2026. From January 1 to June 30, 116 new cosmetic ingredients completed notification and entered the public disclosure stage, representing a 45% year-on-year increase. Among them, 10 ingredients entered the safety monitoring period.   Chemical ingredients (including polymers) remain the dominant category among China's notified NCIs. However, natural and biotech ingredients have gained increasing attention, driven by China's abundant natural resources and the rapid development of biotechnology and synthetic biology in recent years. In H1 2026, 50 plant-derived and 31 biotechnology-derived ingredients completed notification, highlighting the growing innovation in

Recently, ZMUni Compliance Centre successfully supported Scientis in securing approval for its Cyspera® product in China, a Special Cosmetic product with whitening and freckle-removing claims.   Compared with general cosmetics, Special Cosmetics in China are subject to more stringent regulatory requirements, requiring extensive technical documentation, detailed formulation review, safety assessment, efficacy evaluation, and regulatory compliance review. ZMUni provided end-to-end regulatory support throughout the registration process, including dossier preparation and review, compliance assessment, submission support, and regulatory follow-up.   Leveraging its regulatory expertise and efficient project management, ZMUni supported Scientis in successfully completing the registration process and obtaining approval on the

Recently, ZMUni Compliance Centre successfully supported XtalPi Holdings Limited (2228.HK) in securing a U.S. Self-affirmed GRAS determination for Tensotide™, an innovative oral peptide ingredient designed for blood glucose management. Developed through XtalPi's proprietary AI-powered peptide platform PepiX™, Tensotide™ is now cleared for lawful use in foods and dietary supplements in the United States, enabling a significant step forward in its global commercialization pathway.   This milestone represents another key achievement for XtalPi in the consumer health space and highlights ZMUni Compliance Centre's strong capabilities in overseas food regulatory compliance and international market access for novel and innovative ingredients, consistently enabling

Recently, ZMUni Compliance Centre has successfully supported multiple cosmetic brands in navigating and completing regulatory compliance across key global markets—including the United States (and California), Canada, Taiwan (China), Japan, ASEAN (Malaysia, Indonesia, Thailand, Vietnam), and the United Kingdom.   These projects cover a wide range of cosmetic categories, from skincare products such as moisturisers, cleansers, anti-aging, and brightening formulations, to colour cosmetics, haircare, and full-range personal care products.     United States   Our recent compliance achievements in the US market span a diverse range of product categories, including moisturisers, skincare gels and oils, cleansing gels/milks, hydrating masks, serums, clay

ZMUni Compliance Center has recently supported two overseas food manufacturers in successfully completing registration with China’s General Administration of Customs (GACC) as overseas manufacturers of imported food, enabling compliant access to the Chinese market.      Case 1 | LLC First Alive Collagen & Hydrolyzed Collagen Products (Russia)      ZMUni supported LLC "First Alive Collagen" in completing its GACC registration as an overseas food production enterprise. With the registration approved, the company is now eligible to export hydrolyzed collagen products to China, enabling compliant import and customs clearance.   First Alive Collagen is a Russian biotechnology company focused on collagen-based